J&J reaches a $181 million settlement with 36 states and the District of Columbia for off-label marketing of Risperdal. Plaintiffs also claimed that the company downplayed the implied adverse effects of the drug. Also in 2012, Bloomberg news reported on over 400 Risperdal lawsuits filed across the U.S., the vast majority of which alleged gynecomastia injuries. 2012 was also the year J&J offered $2.2 billion to the Department of Justice to call off the investigation.
